JP2019505548A - Ｍｙｃモジュレーターとしてのｍａｘバインダーおよびこれらの使用 - Google Patents
Ｍｙｃモジュレーターとしてのｍａｘバインダーおよびこれらの使用 Download PDFInfo
- Publication number
- JP2019505548A JP2019505548A JP2018543356A JP2018543356A JP2019505548A JP 2019505548 A JP2019505548 A JP 2019505548A JP 2018543356 A JP2018543356 A JP 2018543356A JP 2018543356 A JP2018543356 A JP 2018543356A JP 2019505548 A JP2019505548 A JP 2019505548A
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- formula
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC1(*)NC(CC2)=C2*=C1 Chemical compound CC1(*)NC(CC2)=C2*=C1 0.000 description 4
- BJOMSXNKTOASIL-CQYKKIRKSA-N O=C(CCCCCCCNC(CN(Cc1ccccc1[C@@H]1OC(c2ccccc2)=N[C@@]11Cc2ccccc2)C1=O)=O)Nc1cccc2c1CN(C(CCC(N1)=O)C1=O)C2=O Chemical compound O=C(CCCCCCCNC(CN(Cc1ccccc1[C@@H]1OC(c2ccccc2)=N[C@@]11Cc2ccccc2)C1=O)=O)Nc1cccc2c1CN(C(CCC(N1)=O)C1=O)C2=O BJOMSXNKTOASIL-CQYKKIRKSA-N 0.000 description 1
- LLOLSWXHEXRJCX-VXQZMXDASA-N O=C(CCCCCCCNC(COCCOCCNC(CN(Cc1c([C@@H]2OC(c3ccccc3)=N[C@@]22Cc3ccccc3)cccc1)C2=O)=O)=O)Nc1c(CN(C(CCC(N2)=O)C2=O)C2=O)c2ccc1 Chemical compound O=C(CCCCCCCNC(COCCOCCNC(CN(Cc1c([C@@H]2OC(c3ccccc3)=N[C@@]22Cc3ccccc3)cccc1)C2=O)=O)=O)Nc1c(CN(C(CCC(N2)=O)C2=O)C2=O)c2ccc1 LLOLSWXHEXRJCX-VXQZMXDASA-N 0.000 description 1
- PGPPHSOTYUEHDC-FIBFNYFMSA-N O=C(CCCCNC(CCCCNC(CN(Cc1c([C@@H]2OC(c3ccccc3)=N[C@@]22Cc3ccccc3)cccc1)C2=O)=O)=O)NCCCCC(Nc1c(CN(C(CCC(N2)=O)C2=O)C2=O)c2ccc1)=O Chemical compound O=C(CCCCNC(CCCCNC(CN(Cc1c([C@@H]2OC(c3ccccc3)=N[C@@]22Cc3ccccc3)cccc1)C2=O)=O)=O)NCCCCC(Nc1c(CN(C(CCC(N2)=O)C2=O)C2=O)c2ccc1)=O PGPPHSOTYUEHDC-FIBFNYFMSA-N 0.000 description 1
- NKURJDAWCOCCAD-KIXINCQRSA-N O=C(CCCCNC(CN(Cc1c([C@@H]2OC(c3ccccc3)=N[C@@]22Cc3ccccc3)cccc1)C2=O)=O)NCCCCC(Nc1c(CN(C(CCC(N2)=O)C2=O)C2=O)c2ccc1)=O Chemical compound O=C(CCCCNC(CN(Cc1c([C@@H]2OC(c3ccccc3)=N[C@@]22Cc3ccccc3)cccc1)C2=O)=O)NCCCCC(Nc1c(CN(C(CCC(N2)=O)C2=O)C2=O)c2ccc1)=O NKURJDAWCOCCAD-KIXINCQRSA-N 0.000 description 1
- CVHDOKXPCXYTRG-UPDBPMCLSA-N O=C(CN(CC(C=CCC1)=C1[C@@H]1OC(c2ccccc2)=N[C@@]11Cc2ccccc2)C1=O)NCCOCCOCC(Nc1c(CN(C(CCC(N2)=O)C2=O)C2=O)c2ccc1)=O Chemical compound O=C(CN(CC(C=CCC1)=C1[C@@H]1OC(c2ccccc2)=N[C@@]11Cc2ccccc2)C1=O)NCCOCCOCC(Nc1c(CN(C(CCC(N2)=O)C2=O)C2=O)c2ccc1)=O CVHDOKXPCXYTRG-UPDBPMCLSA-N 0.000 description 1
- MTBWMEVPVUBCKW-ASOATCDWSA-N O=C(CN(Cc1ccccc1[C@@H]1OC(c2ccccc2)=N[C@@]11Cc2ccccc2)C1=O)NCCOCC(Nc1c(CN(C(CCC(N2)=O)C2=O)C2=O)c2ccc1)=O Chemical compound O=C(CN(Cc1ccccc1[C@@H]1OC(c2ccccc2)=N[C@@]11Cc2ccccc2)C1=O)NCCOCC(Nc1c(CN(C(CCC(N2)=O)C2=O)C2=O)c2ccc1)=O MTBWMEVPVUBCKW-ASOATCDWSA-N 0.000 description 1
- NTACAUGEYBWLLI-NPAIPGMDSA-N O=C(CN(Cc1ccccc1[C@@H]1OC(c2ccccc2)=N[C@@]11Cc2ccccc2)C1=O)NCCOCCOCCOCCOCC(Nc1c(CN(C(CCC(N2)=O)C2=O)C2=O)c2ccc1)=O Chemical compound O=C(CN(Cc1ccccc1[C@@H]1OC(c2ccccc2)=N[C@@]11Cc2ccccc2)C1=O)NCCOCCOCCOCCOCC(Nc1c(CN(C(CCC(N2)=O)C2=O)C2=O)c2ccc1)=O NTACAUGEYBWLLI-NPAIPGMDSA-N 0.000 description 1
- UEYPWWNXNLJHQI-NCOUYRBYSA-N O=C([C@@]1(CC2COC2)N=C(c(cc2)ccc2-c(cc2)ccc2S(CCN(Cc2ccccc2[C@@H]2OC(c3ccccc3)=N[C@@]22CN3CCOCC3)C2=O)(=O)=O)O[C@H]11)N(CCS(c2ccccc2)(=O)=O)Cc2c1cccc2 Chemical compound O=C([C@@]1(CC2COC2)N=C(c(cc2)ccc2-c(cc2)ccc2S(CCN(Cc2ccccc2[C@@H]2OC(c3ccccc3)=N[C@@]22CN3CCOCC3)C2=O)(=O)=O)O[C@H]11)N(CCS(c2ccccc2)(=O)=O)Cc2c1cccc2 UEYPWWNXNLJHQI-NCOUYRBYSA-N 0.000 description 1
- IYNRVKJLZPPQDJ-SHUZPENHSA-N O=C1N(CCS(c2ccccc2)(=O)=O)Cc2ccccc2[C@@H]2OC(c3ccc(C4COC4)cc3)=N[C@]12Cc1ccccc1 Chemical compound O=C1N(CCS(c2ccccc2)(=O)=O)Cc2ccccc2[C@@H]2OC(c3ccc(C4COC4)cc3)=N[C@]12Cc1ccccc1 IYNRVKJLZPPQDJ-SHUZPENHSA-N 0.000 description 1
- IJWCGUBROYFHHO-IZEXYCQBSA-N O=C1N(CCS(c2ccccc2)(=O)=O)Cc2ccccc2[C@@H]2OC(c3cccnc3)=N[C@]12Cc1ccccc1 Chemical compound O=C1N(CCS(c2ccccc2)(=O)=O)Cc2ccccc2[C@@H]2OC(c3cccnc3)=N[C@]12Cc1ccccc1 IJWCGUBROYFHHO-IZEXYCQBSA-N 0.000 description 1
- QUQYIOWMOQFCEU-SVEHJYQDSA-N O=C1N(CCS(c2ccccc2)(=O)=O)Cc2ccccc2[C@@H]2OC(c3ncc[s]3)=N[C@]12Cc1ccccc1 Chemical compound O=C1N(CCS(c2ccccc2)(=O)=O)Cc2ccccc2[C@@H]2OC(c3ncc[s]3)=N[C@]12Cc1ccccc1 QUQYIOWMOQFCEU-SVEHJYQDSA-N 0.000 description 1
- LNLQYQDHVMDEMU-AHWVRZQESA-N O=C1N(CCS(c2ccccc2)(=O)=O)Cc2ccccc2[C@@H]2OC=N[C@]12Cc1ccccc1 Chemical compound O=C1N(CCS(c2ccccc2)(=O)=O)Cc2ccccc2[C@@H]2OC=N[C@]12Cc1ccccc1 LNLQYQDHVMDEMU-AHWVRZQESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662295996P | 2016-02-16 | 2016-02-16 | |
| US62/295,996 | 2016-02-16 | ||
| PCT/US2017/018162 WO2017143059A1 (en) | 2016-02-16 | 2017-02-16 | Max binders as myc modulators and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019505548A true JP2019505548A (ja) | 2019-02-28 |
| JP2019505548A5 JP2019505548A5 (enExample) | 2020-03-26 |
Family
ID=58191662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543356A Pending JP2019505548A (ja) | 2016-02-16 | 2017-02-16 | Ｍｙｃモジュレーターとしてのｍａｘバインダーおよびこれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10106555B2 (enExample) |
| EP (1) | EP3416950A1 (enExample) |
| JP (1) | JP2019505548A (enExample) |
| KR (1) | KR20180107261A (enExample) |
| CN (1) | CN109071456A (enExample) |
| AU (1) | AU2017221422A1 (enExample) |
| BR (1) | BR112018016133A2 (enExample) |
| CA (1) | CA3012846A1 (enExample) |
| MX (1) | MX2018009913A (enExample) |
| RU (1) | RU2018132559A (enExample) |
| WO (1) | WO2017143059A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025118594A (ja) * | 2019-11-08 | 2025-08-13 | サンフォード バーンハム プレビス メディカル ディスカバリー インスティテュート | アポトーシス阻害（ｉａｐ）タンパク質アンタゴニスト |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2018132559A (ru) | 2016-02-16 | 2020-03-17 | Массачусетс Инститьют Оф Текнолоджи | Связывающие молекулы для max в качестве модуляторов myc и их применения |
| EP3820847B1 (en) * | 2018-07-09 | 2022-12-14 | The Scripps Research Institute | Improved compounds for myc inhibition |
| CN111274691A (zh) * | 2020-01-16 | 2020-06-12 | 西安交通大学 | 一种分析预测max相材料可形成能力的方法 |
| WO2021195360A1 (en) | 2020-03-27 | 2021-09-30 | Landos Biopharma, Inc. | Plxdc2 ligands |
| CN117242060B (zh) | 2021-01-13 | 2026-07-17 | 蒙特罗莎治疗股份有限公司 | 异吲哚啉酮化合物 |
| CN116908444B (zh) * | 2023-09-13 | 2023-12-19 | 中国医学科学院北京协和医院 | 血浆max自身抗体在晚期非小细胞肺癌pd-1单抗联合化疗治疗预后预测中的应用 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02191695A (ja) | 1989-01-20 | 1990-07-27 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02194085A (ja) | 1989-01-24 | 1990-07-31 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02196887A (ja) | 1989-01-26 | 1990-08-03 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02208392A (ja) | 1989-02-08 | 1990-08-17 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02222488A (ja) | 1989-02-23 | 1990-09-05 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02227489A (ja) | 1989-02-28 | 1990-09-10 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02227490A (ja) | 1989-02-28 | 1990-09-10 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02227491A (ja) | 1989-03-01 | 1990-09-10 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02242882A (ja) | 1989-03-16 | 1990-09-27 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02247280A (ja) | 1989-03-20 | 1990-10-03 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02247282A (ja) | 1989-03-22 | 1990-10-03 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02255794A (ja) | 1989-03-29 | 1990-10-16 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| JPH02255793A (ja) | 1989-03-30 | 1990-10-16 | Dainippon Ink & Chem Inc | 強誘電性液晶組成物 |
| US5965574A (en) | 1996-08-13 | 1999-10-12 | Chen; Yuhpyng Liang | Heteroaryl amines as novel acetylcholinesterase inhibitors |
| JPH08231541A (ja) | 1995-03-01 | 1996-09-10 | Nippon Soda Co Ltd | イミダゾリン誘導体および除草剤 |
| WO2000018746A1 (en) | 1998-09-30 | 2000-04-06 | Roche Diagnostics Gmbh | Thiazolidine derivatives for the treatment and prevention of metabolic bone disorders |
| EP1123297A1 (en) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | New compounds, their preparation and use |
| WO2002049632A1 (en) | 2000-12-18 | 2002-06-27 | Institute Of Medicinal Molecular Design. Inc. | Inhibitors against the production and release of inflammatory cytokines |
| US6452014B1 (en) | 2000-12-22 | 2002-09-17 | Geron Corporation | Telomerase inhibitors and methods of their use |
| JP2003057783A (ja) | 2001-08-21 | 2003-02-26 | Konica Corp | 銀色調を改良した光熱写真画像形成材料 |
| JP2003075955A (ja) | 2001-09-03 | 2003-03-12 | Konica Corp | 銀色調を改良した光熱写真画像形成材料 |
| JP2003075957A (ja) | 2001-09-07 | 2003-03-12 | Konica Corp | スケイル模様のない光熱写真画像形成材料 |
| ATE363278T1 (de) | 2001-09-14 | 2007-06-15 | Novo Nordisk As | Neue liganden für die hisb10 zn2+ stellen des insulin-hexamers in der r-konformation |
| US20050042674A9 (en) | 2002-02-21 | 2005-02-24 | Lin Yu | Common ligand mimics: thiazolidinediones and rhodanines |
| GB2387172A (en) | 2002-03-28 | 2003-10-08 | Pantherix Ltd | [(Aryl-/arylthio-)aryl]methylene substituted azole & azine derivatives and their therapeutic use as antibacterials |
| AU2003291613B2 (en) | 2002-04-30 | 2007-09-27 | Merck & Co., Inc. | Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers |
| JP4211433B2 (ja) | 2002-08-14 | 2009-01-21 | 三菱化学株式会社 | 有機金属錯体、発光色素、有機電界発光素子材料および有機電界発光素子 |
| WO2004080989A1 (ja) | 2003-03-10 | 2004-09-23 | Sumitomo Chemical Company Limited | フラン化合物の製造方法 |
| US7777051B2 (en) | 2003-05-13 | 2010-08-17 | Icagen, Inc. | Asymmetric benzimidazoles and related compounds as potassium channel modulators |
| US20060074124A1 (en) | 2003-09-12 | 2006-04-06 | Andrew Napper | Methods of treating a disorder |
| WO2005026112A2 (en) | 2003-09-12 | 2005-03-24 | Elixir Pharmaceuticals, Inc. | Methods of treating a disorder |
| WO2005033090A1 (ja) | 2003-10-06 | 2005-04-14 | Sumitomo Chemical Company, Limited | 芳香族化合物 |
| WO2006005683A1 (en) | 2004-07-09 | 2006-01-19 | Novo Nordisk A/S | Phamaceutical preparations comprising insulin |
| JP2006084592A (ja) | 2004-09-14 | 2006-03-30 | Fuji Photo Film Co Ltd | 感光性組成物 |
| PT1746097E (pt) | 2005-07-20 | 2010-04-15 | Aventis Pharma Sa | Heterociclos fundidos de 1,4-di-hidropiridina, processo para a sua preparação, utilização e composições que os contêm |
| US20090022694A1 (en) | 2005-10-18 | 2009-01-22 | Distefano Peter | Sirt1 inhibition |
| JP4931434B2 (ja) | 2006-02-14 | 2012-05-16 | 株式会社ダイセル | アミノ基含有アダマンタン誘導体とその製造方法 |
| EP2035005A4 (en) | 2006-06-09 | 2011-07-06 | Kemia Inc | THERAPY BASED ON CYTOKINE INHIBITORS |
| WO2008012010A1 (en) | 2006-07-27 | 2008-01-31 | Ucb Pharma, S.A. | Fused oxazoles & thiazoles as histamine h3- receptor ligands |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| EA201001205A1 (ru) | 2008-01-24 | 2011-04-29 | Юсб Фарма, С.А. | Соединения, содержащие циклобутоксигруппу |
| WO2009108905A2 (en) | 2008-02-28 | 2009-09-03 | Life Technologies Corporation | Fluorescence polarization herg assay |
| KR101712576B1 (ko) | 2008-11-10 | 2017-03-06 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｒ 키나제의 억제제로서 유용한 화합물 |
| US8865909B2 (en) | 2008-11-20 | 2014-10-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Anti-biofilm agents |
| US20120040916A1 (en) | 2008-12-22 | 2012-02-16 | Massachusetts Institute Of Technology | Molecular inhibitors of the wnt/beta-catenin pathway |
| JP5046213B2 (ja) | 2009-03-12 | 2012-10-10 | 独立行政法人科学技術振興機構 | 光学活性アルコール化合物の製法 |
| WO2011063502A1 (en) | 2009-11-24 | 2011-06-03 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
| PL2509602T3 (pl) | 2009-12-04 | 2017-08-31 | Senhwa Biosciences, Inc. | Pirazolopirymidyny i podobne heterocykle jako inhibitory ck2 |
| KR101889993B1 (ko) | 2010-09-10 | 2018-08-20 | 시오노기세야쿠 가부시키가이샤 | Ａｍｐｋ 활성화 작용을 갖는 헤테로환 축합 이미다졸 유도체 |
| KR20140093607A (ko) | 2011-05-11 | 2014-07-28 | 이데미쓰 고산 가부시키가이샤 | 신규 화합물, 유기 전기발광 소자용 재료 및 유기 전기발광 소자 |
| KR20140060484A (ko) | 2011-09-13 | 2014-05-20 | 이데미쓰 고산 가부시키가이샤 | 축합 복소 방향족 유도체, 유기 전계 발광 소자용 재료 및 그것을 이용한 유기 전계 발광 소자 |
| JP6653573B2 (ja) | 2012-05-22 | 2020-02-26 | トラスティーズ・オブ・ダートマウス・カレッジ | シクロアルカニル［ｂ］インドール、シクロアルカニル［ｂ］ベンゾフラン、シクロアルカニル［ｂ］ベンゾチオフェンを合成するための方法、化合物および使用の方法 |
| LT3418281T (lt) * | 2012-12-07 | 2021-01-11 | Vertex Pharmaceuticals Inc. | Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui |
| US9573963B2 (en) | 2013-02-28 | 2017-02-21 | Sumitomo Chemical Company, Limited | Fused heterocyclic compound and pest control applications thereof |
| US8901164B2 (en) * | 2013-03-07 | 2014-12-02 | University Of Maryland, Baltimore | Amphipathic and other double-sided alpha-helix mimetics based on a 1,2-diphenylacetylene scaffold |
| EA201591746A1 (ru) | 2013-03-14 | 2016-08-31 | КОНВЕРДЖЕН ЭлЭлСи | Способы и композиции для ингибирования бромодомен-содержащих белков |
| US9242944B2 (en) | 2013-03-27 | 2016-01-26 | University Of Maryland, Baltimore | Potent analogues of the C-Myc inhibitor 10074-G5 with improved cell permeability |
| CA2942574A1 (en) | 2013-12-11 | 2015-06-18 | The Scripps Research Institute | Small molecule c-myc inhibitors |
| CA2968884A1 (en) | 2014-12-10 | 2016-06-16 | Massachusetts Institute Of Technology | Fused 1,3-azole derivatives useful for the treatment of proliferative diseases |
| RU2018132559A (ru) | 2016-02-16 | 2020-03-17 | Массачусетс Инститьют Оф Текнолоджи | Связывающие молекулы для max в качестве модуляторов myc и их применения |
-
2017
- 2017-02-16 RU RU2018132559A patent/RU2018132559A/ru not_active Application Discontinuation
- 2017-02-16 CA CA3012846A patent/CA3012846A1/en not_active Abandoned
- 2017-02-16 JP JP2018543356A patent/JP2019505548A/ja active Pending
- 2017-02-16 KR KR1020187026354A patent/KR20180107261A/ko not_active Withdrawn
- 2017-02-16 US US15/435,003 patent/US10106555B2/en active Active
- 2017-02-16 AU AU2017221422A patent/AU2017221422A1/en not_active Abandoned
- 2017-02-16 MX MX2018009913A patent/MX2018009913A/es unknown
- 2017-02-16 BR BR112018016133A patent/BR112018016133A2/pt not_active Application Discontinuation
- 2017-02-16 CN CN201780011783.5A patent/CN109071456A/zh active Pending
- 2017-02-16 EP EP17708095.9A patent/EP3416950A1/en not_active Withdrawn
- 2017-02-16 WO PCT/US2017/018162 patent/WO2017143059A1/en not_active Ceased
-
2018
- 2018-10-22 US US16/167,238 patent/US10865213B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025118594A (ja) * | 2019-11-08 | 2025-08-13 | サンフォード バーンハム プレビス メディカル ディスカバリー インスティテュート | アポトーシス阻害（ｉａｐ）タンパク質アンタゴニスト |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018009913A (es) | 2018-11-29 |
| US20170233405A1 (en) | 2017-08-17 |
| WO2017143059A1 (en) | 2017-08-24 |
| US20190144466A1 (en) | 2019-05-16 |
| US10865213B2 (en) | 2020-12-15 |
| US10106555B2 (en) | 2018-10-23 |
| EP3416950A1 (en) | 2018-12-26 |
| RU2018132559A (ru) | 2020-03-17 |
| KR20180107261A (ko) | 2018-10-01 |
| BR112018016133A2 (pt) | 2019-01-02 |
| AU2017221422A1 (en) | 2018-08-16 |
| CN109071456A (zh) | 2018-12-21 |
| CA3012846A1 (en) | 2017-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7308146B2 (ja) | インターロイキン１受容体関連キナーゼの阻害剤およびその使用 | |
| JP7258748B2 (ja) | サイクリン依存性キナーゼ１２（ｃｄｋ１２）の阻害剤およびその使用 | |
| JP6989505B2 (ja) | Ｍａｌｔ１阻害剤およびその使用 | |
| US10017520B2 (en) | Myc modulators and uses thereof | |
| US20220227734A1 (en) | Degraders of cyclin-dependent kinase 12 (cdk12) and uses thereof | |
| US10865213B2 (en) | Max binders as MYC modulators and uses thereof | |
| JP2019514884A (ja) | Ｅｚｈ２インヒビターおよびそれらの使用 | |
| JP7821573B2 (ja) | Ｄｏｔ１ｌディグレーダーおよびその使用 | |
| CN111825611A (zh) | 4(1h)-奎诺酮衍生物及其用途 | |
| JP7185631B2 (ja) | 抗線維化化合物 | |
| JP2021514955A (ja) | プロテアソーム関連ユビキチン受容体ｒｐｎ１３機能を阻止する低分子およびその使用法 | |
| AU2019318046B2 (en) | Histone demethylase 5 inhibitors and uses thereof | |
| AU2020205665C1 (en) | DOT1L degraders and uses thereof | |
| JP2018538364A (ja) | ポリアミンスルホンアミドおよびこれらの使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200217 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200217 |